Jubb, Adrian M <br/><br/>
Biomarkers to predict the clinical efficacy of bevacizumab in cancer.  [electronic resource] 

 -  The Lancet. Oncology  Dec 2010 
 - 1172-83 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(10)70232-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Bevacizumab<br/>Biomarkers, Tumor--blood<br/>Clinical Trials, Phase III as Topic<br/>Humans<br/>Neoplasms--drug therapy<br/>Polymorphism, Genetic<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--genetics